SCHEMBL2564475

SCHEMBL2564475

CCN(CC)CCOc1cc(I)c(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
BIRC5 O15392 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD3 P35462 1/20 0.40
HSP90AB1 P08238 2/20 0.40
KCNH2 Q12809 1/20 0.40
HSP90AA1 P07900 1/20 0.39
CYP2C19 P33261 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KDR P35968 1/20 0.38
MAPT P10636 1/20 0.38
CHRNA7 P36544 1/20 0.38
KMT2A Q03164 1/20 0.38
AGER Q15109 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11207045 0.94 KDM4E (0.44) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1
SCHEMBL13745019 0.82 KDM4E (0.53) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1
SCHEMBL12161089 0.80 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1TDP1DRD1DRD3
SCHEMBL7940396 0.75 HPGD (0.57) KDM4EBIRC5SMN1; SMN2ALDH1A1CYP2C19
SCHEMBL6142499 0.73 BIRC5 (0.50) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1
SCHEMBL3857536 0.73 MAOA (0.57) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1
SCHEMBL4591966 0.73 KDR (0.56) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1
SCHEMBL4592183 0.73 KDM4E (0.58) KDM4EBIRC5SMN1; SMN2SIGMAR1MAPT
SCHEMBL5433176 0.73 KDM4E (0.55) KDM4EBIRC5SMN1; SMN2SIGMAR1MAPT
SCHEMBL13602317 0.72 KDM4E (0.53) KDM4EBIRC5SMN1; SMN2ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007767-B1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS R&D LTD (GB) 2011-11-02 EP disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
EP-2007767-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R&D) LTD (GB) 2008-12-31 EP disclosed
WO-2007104944-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors HSP90AA1, HSP90AB1, RAF1 KDM4E 3672/4885BIRC5 1384/4885SMN1; SMN2 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.